The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBILB.L Regulatory News (BILB)

  • There is currently no data for BILB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding and Share Plan

11 Mar 2021 09:11

RNS Number : 9404R
Bilby PLC
11 March 2021
 

11 March 2021

 

 

 

Bilby Plc

("Bilby" or the "Company")

 

Director/PDMR Shareholding and Share Plan

 

Bilby Plc (AIM: BILB), a leading supplier of gas heating, electrical and building services, is pleased to announce the making of further awards under the Company's established CSOP Plan (the "CSOP Plan") and JSOP Plan (the "JSOP Plan").

 

The Company has granted options under the CSOP Plan on 5 March 2021 in the following quantities to the following Directors:

 

Director/PDMR

Options Granted

Exercise price

David Bullen

85,714

35p

Clive Lovett

85,714

35p

Lee Venables

85,714

35p

 

 

The following table also sets out the number of new ordinary shares ("Ordinary Shares") issued and jointly acquired by each of the named directors and the trustee of The Bilby Employees' Share Trust ("the Trust") under the JSOP Plan on 5 March 2021 at a subscription price of 35 pence per Ordinary Share, being the closing price of an Ordinary Share in the Company on 04 March 2021.

 

Director/PDMR

Ordinary Shares

Subscription Price

David Bullen

1,414,286

35p per Ordinary Share

Clive Lovett

414,286

35p per Ordinary Share

Lee Venables

414,286

35p per Ordinary Share

 

 

The vesting of the Jointly Owned Shares is conditional on the achievement of specific performance conditions for the following financial and shareholder return metrics: a minimum 25% compound annual growth rate in both earnings per share and cash generated from operating activities as well as share price targets.

Further, the Jointly Owned Shares will become vested only if the participant remains with the Company for a minimum period of 3 years.

Application has been made to the London Stock Exchange for 2,242,858 new Ordinary Shares to be admitted to trading on AIM ("Admission") and Admission is expected to become effective on 16 March 2021.

 

Following Admission, the beneficial interests held by each of the directors will be:

 

Director/PDMR

No. of whole Shares in which the Director is interested

No. of Shares in which the Director has an interest under the terms of a JOA

David Bullen

2,888,773

1,664,286

Clive Lovett

868,831

414,286

Lee Venables

962,948

414,286

 

 

The Ordinary Shares represent 3.7% of the Company's issued share capital following grant.

 

Bilby advises that, following Admission of the 2,242,858 Ordinary Shares, the issued share capital of the Company will be 61,214,703 Ordinary Shares with one voting right each. The Company does not hold any shares in treasury.

 

The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Sangita Shah, Chair, Bilby plc, commented:

 

"I am pleased to announce the last pillar of our share incentive arrangements for the Group. The prioritisation of our workforce saw the introduction of a Company-wide Share Incentive Plan in August 2020 with 30% of our employees embracing the opportunity to participate, followed in October 2020 by the roll out of a Company Share Option Plan with 15% of our employees now participating. As a final step through the Joint Share Ownership Plan, we recognise our Executive Team, who have worked assiduously to revive the business into one which is poised for sustainable growth.

 

The Executive Team have been required to make an immediate upfront financial commitment to participate in the Joint Share Ownership Plan for a vesting that will occur in three years' time, only subject to performance targets, demonstrating their confidence, purpose and dedication to the journey ahead.

 

The broad inclusion of all employees, particularly our front-line staff of Engineers and Call Administrators, reflects our commitment to create a culture of share ownership, align our staff with shareholder's interests and ensure that our staff are rewarded by sharing in the success of our business."

 

 

 

Enquiries

 

Bilby Plc

Sangita Shah, Chairman

David Bullen, Chief Executive Officer

+44 (0)20 7796 4133

(via Hudson Sandler)

 

Canaccord Genuity Limited (Nominated Adviser and Sole Broker)

 

+44 (0)20 7523 8000

Corporate Broking: Bobbie Hilliam Andrew Potts Georgina McCooke

 

Sales: Jonathan Barr

Hudson Sandler (Financial PR)

+44 (0)20 7796 4133

Charlie Jack

Bertie Berger

 

 

 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

David Bullen

2.

Reason for the Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

LEI

213800JDWVCVYWS87928

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares

Identification code

GB00BV9GHQ09

b)

Nature of the transaction

Issue of Ordinary Shares

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

35p

1,500,000

d)

Aggregated information:

Aggregated volume

Price

1,500,000 Ordinary Shares issued at a price of 35 pence per Ordinary Share

e)

Date of the transaction

10 March 2021

f)

Place of the transaction

London Stock Exchange (XLON)

 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Clive Lovett

2.

Reason for the Notification

a)

Position/status

Group Finance Director

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

LEI

213800JDWVCVYWS87928

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares

Identification code

GB00BV9GHQ09

b)

Nature of the transaction

Issue of Ordinary Shares

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

35p

500,000

d)

Aggregated information:

Aggregated volume

Price

500,000 Ordinary Shares issued at a price of 35 pence per Ordinary Share

e)

Date of the transaction

10 March 2021

f)

Place of the transaction

London Stock Exchange (XLON)

 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Lee Venables

2.

Reason for the Notification

a)

Position/status

Chief Operating Officer

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

b)

LEI

213800JDWVCVYWS87928

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares

Identification code

GB00BV9GHQ09

b)

Nature of the transaction

Issue of Ordinary Shares

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

35p

500,000

d)

Aggregated information:

Aggregated volume

Price

500,000 Ordinary Shares issued at a price of 35 pence per Ordinary Share

e)

Date of the transaction

10 March 2021

f)

Place of the transaction

London Stock Exchange (XLON)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCJBMLTMTBBMMB
Date   Source Headline
16th Jun 20214:46 pmRNSChange of name to Kinovo plc
24th May 20216:12 pmRNSDirector/PDMR Shareholding
12th May 20214:57 pmRNSDirector/PDMR Shareholding
6th May 202110:09 amRNSHolding(s) in Company
6th May 20217:00 amRNSYear-end trading update
15th Apr 20214:41 pmRNSSecond Price Monitoring Extn
15th Apr 20214:35 pmRNSPrice Monitoring Extension
30th Mar 20217:00 amRNSDirector/PDMR Shareholding
23rd Mar 20214:16 pmRNSHolding(s) in Company
18th Mar 20212:01 pmRNSHolding(s) in Company
12th Mar 20214:41 pmRNSSecond Price Monitoring Extn
12th Mar 20214:36 pmRNSPrice Monitoring Extension
11th Mar 20219:37 amRNSHolding(s) in Company
11th Mar 20219:11 amRNSDirector/PDMR Shareholding and Share Plan
8th Feb 20214:49 pmRNSHolding(s) in Company
28th Jan 20213:58 pmRNSHolding(s) in Company
24th Dec 20207:00 amRNSJoint Share Ownership Plan
1st Dec 20207:00 amRNSHalf Year results
13th Nov 20207:00 amRNSTrading update and Board restructure
14th Oct 20204:40 pmRNSHolding(s) in Company
12th Oct 20208:15 amRNSHolding(s) in Company
5th Oct 202011:04 amRNSReplacement: Holding(s) in Company
30th Sep 202011:33 amRNSHolding(s) in Company
30th Sep 202011:28 amRNSHolding(s) in Company
16th Sep 20206:07 pmRNSDirector/PDMR Shareholding
14th Sep 202011:34 amRNSResult of AGM
11th Sep 202010:07 amRNSBoard change
14th Aug 202011:08 amRNSHolding(s) in Company
14th Aug 202010:35 amRNSAnnual Report and Notice of AGM
27th Jul 20201:27 pmRNSHolding(s) in Company
27th Jul 20207:00 amRNSFull Year Results
16th Jul 20207:00 amRNSNotice of Results
26th May 20208:06 amRNSNew Banking Facilities
7th May 20207:00 amRNSDirector/PDMR Shareholding
28th Apr 20203:44 pmRNSDirector/PDMR Shareholding
24th Apr 20207:00 amRNSYear-end and COVID-19 trading update
1st Apr 20204:41 pmRNSSecond Price Monitoring Extn
1st Apr 20204:36 pmRNSPrice Monitoring Extension
11th Mar 20203:41 pmRNSDirector/PDMR Shareholding
19th Dec 20197:00 amRNSInterim Results
3rd Dec 20194:48 pmRNSNotice of Results
25th Nov 20197:00 amRNSDirectorate Change
22nd Nov 20197:00 amRNSHolding(s) in Company
21st Nov 201912:07 pmRNSHolding(s) in Company
20th Nov 20195:40 pmRNSHolding(s) in Company
20th Nov 20194:40 pmRNSHolding(s) in Company
15th Nov 20198:02 amRNSResult of Fundraise
14th Nov 20194:52 pmRNSProposed Fundraise
28th Oct 20194:21 pmRNSResult of Annual General Meeting
30th Sep 201911:59 amRNSAnnual Report and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.